<i>B</i> leeding <i>R</i> isk <i>A</i> nalysis in <i>S</i> troke <i>I</i> maging Before Thrombo <i>L</i> ysis (BRASIL)

Abstract

The data suggest that if there is any increased risk of SICH attributable to CMBs, it is likely to be small and unlikely to exceed the benefits of thrombolytic therapy. No reliable conclusion regarding risk in the rare patient with multiple CMBs can be reached.